US Stocks Movement | Vir Biotechnology Surges Over 38% to Hit Highest Level in Over a Year, Q4 Revenue Soars 417% Year-on-Year, Exceeding Expectations

Glonghui, February 24｜Vir Biotechnology (VIR.US) once surged over 38%, reaching a high of $10.29, marking a new one-year high. In terms of news, Vir Biotechnology's fourth-quarter revenue was $64.07 million, a year-on-year increase of 417%, while the market expectation was $44.16 million; the loss per share was $0.31, compared to a loss of $0.76 per share in the same period last year. In addition, the company announced positive results in the Phase 1 clinical trial of VIR-5500, an investigational therapy for the treatment of late-stage metastatic castration-resistant prostate cancer. (Glonghui)